GSK Reports the NMPA’s NDA Acceptance with Priority Review of Linerixibat for Cholestatic Pruritus
GlaxoSmithKline announced that China’s National Medical Products Administration has accepted the New Drug Application for linerixibat and placed it under priority review for treating cholestatic pruritus in primary biliary cholangitis (PBC). The filing is backed by the Phase III GLISTEN trial, which demonstrated rapid, sustained itch relief and reduced sleep interference. Regulatory reviews are also progressing in the United States, Europe, the United Kingdom and Canada. The data were presented at the EASL 2025 conference, underscoring the drug’s clinical promise.
Merck Animal Health’s Numelvi Secures the FDA Approval for Control of Pruritus Associated with Allergic Dermatitis in Dogs
Merck Animal Health announced that the U.S. FDA has approved Numelvi (atinvicitinib) for controlling pruritus linked to allergic dermatitis in dogs six months and older, with commercial availability slated for spring 2026. Numelvi is a second‑generation JAK inhibitor that demonstrates...
New Test Could Help Pinpoint IBD Diagnosis, Study Finds
Researchers at the University of Edinburgh have created a luminescent reporter that detects granzyme A activity in stool samples, offering a rapid, non‑invasive marker of gut inflammation. In a trial of 150 specimens, the new assay combined with standard faecal calprotectin...
STAT+: Rare Disease Advocates Fume over FDA’s Mixed Signals
The FDA has rejected Regenxbio’s gene therapy for mucopolysaccharidosis type 2, citing a need for additional data that could postpone approval by years. This decision adds to at least four other recent rejections of cell or gene therapies targeting deadly rare...
Mahzi Doses First Patient in MZ-1866 Trial for Pitt Hopkins Syndrome
Mahzi Therapeutics has administered the first dose of its investigational gene therapy MZ-1866 in the Phase I/II UNITE study for Pitt‑Hopkins syndrome. The open‑label, multicentre trial will enroll roughly 12 genetically confirmed patients across sites in Spain, Israel and the...
With TrumpRx Is America Reforming Its Pharmaceutical Market, or Simply Rebranding Prices?
The Trump administration launched TrumpRx, a website aggregating manufacturer discounts on 43 brand‑name drugs and touting presidential credit for lower patient costs. Early analysis shows that 20 of the listed products already have cheaper generic versions, and the portal deliberately...
Sword Intelligence Launches in the UK, Bringing Proven National-Scale AI Care Operations Set to Transform Healthcare in Greece
Sword Intelligence has launched its AI‑driven care‑operations platform in the UK, targeting NHS waiting‑list pressures. The solution automates triage, coordination, outreach and scheduling, freeing clinical capacity without major staffing or infrastructure upgrades. Simultaneously, the company is building one of Europe’s...
The Hydrothermal Treatment Effect on the Transverse Relaxivity Values of DyF3 Nanoparticles Colloidal Solutions
Researchers investigated how hydrothermal processing—both classic autoclave and microwave irradiation—affects the transverse relaxivity (r₂) of DyF₃ nanoparticle colloids. Using ¹H NMR at magnetic fields of 0.6 T, 3.65 T and 9.4 T, they found that autoclave‑treated samples exhibit the highest r₂ values, outperforming...
10 Companies Hiring in San Francisco and South San Francisco
San Francisco and South San Francisco remain biotech hubs, employing over 113,700 workers according to a Cushman & Wakefield report. Although BioSpace job postings fell sharply in January, listings are now climbing, with ten companies actively hiring. Companies such as AbbVie, Amgen, Eli Lilly and Ideaya...
Argenx Reports Topline P-III (ADAPT OCULUS) Trial Data on Vyvgart in Ocular Myasthenia Gravis (MG)
argenx announced topline Phase III ADAPT OCULUS data for Vyvgart (efgartigimod alfa + hyaluronidase‑qvfc) in adults with ocular myasthenia gravis. The trial met its primary endpoint, delivering a 4.04‑point improvement in Myasthenia Impairment Index PRO ocular scores versus 1.99 points for placebo at...
Accelerating Digital Maturity in Residential Aged Care
Whiddon, a leading residential aged‑care provider in NSW and southeast Queensland, has deployed Telstra Health’s centralised care‑planning platform across its 24 homes. The system enables real‑time, point‑of‑care documentation, family portals and mobile workflows, replacing legacy paper‑based processes. By achieving data...
MHRA Says AI Innovation and Regulation Must Work Together
The UK Medicines and Healthcare products Regulatory Agency (MHRA) is urging that AI innovation in healthcare be paired with robust regulation to safeguard patient safety and equity. Richard Stubbs, CEO of Health Innovation Yorkshire and Humber, highlighted the need for...
Bird Flu Is Back. Here’s What You Need To Know.
Governor Josh Shapiro convened a crisis response after Pennsylvania reported roughly 7.6 million birds infected with avian influenza, prompting a coordinated effort with the USDA and veterinary specialists to contain the outbreak and explore vaccine options. Simultaneously, H5N1 cases have emerged...
Sigma’s Double-Digit Sales, Profit Growth ‘Proves’ Merger Decision
Sigma Healthcare reported double‑digit growth in its first‑half fiscal results, driven by the Chemist Warehouse network. Revenue rose 15% to $5.5 billion, normalised EBIT increased 18.7% to $582.9 million, and NPAT grew 19.2% to $392 million. Chemist Warehouse sales jumped 17.2% to $5.1 billion,...
The Team Behind H.A.L.O. Wins UHN’s Inventor of the Year Award
An interdisciplinary team at University Health Network (UHN) received the Mission of Excellence Team Inventor of the Year Award for creating H.A.L.O., a remote patient monitoring system. Launched as a company in early 2025, H.A.L.O. now operates across 50 inpatient...
Schroeder Ambulatory Centre Aims to Reduce Backlogs
The Schroeder Ambulatory Centre (SAC), a $300 million private non‑profit facility in Richmond Hill, Ontario, has opened its doors with operating rooms, MRI, CT and GI endoscopy capabilities while awaiting full accreditation. It secured $14 million from the provincial government to deliver...
Medicare GME Funding Reform Debate Focuses on Rural Hospitals
A congressional hearing highlighted that current Medicare GME funding formulas leave rural hospitals like Phelps Health struggling to bridge the $5‑$7 million gap between planning grants and accreditation costs. Hospital leaders argue that outdated per‑resident caps and rigid grant structures create...
Trillium Health Partners Deploys Clinical AI to Provide Faster, Safer Care
Trillium Health Partners has launched a clinical AI application that automatically detects intracranial hemorrhage on head CT scans, flagging urgent cases in real time. The tool, sourced through Sectra Amplifier Services, also identifies midline shift, mass effect and skull fractures,...
Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Transcript
Emergent BioSolutions reported a successful completion of its stabilization phase, cutting net debt by $156 million and improving leverage to 3.3x adjusted EBITDA. Adjusted EBITDA surged to $183 million, a $205 million swing from the prior year, while operating cash...
Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Transcript
Ascendis (SNDX) reported €720 million total 2025 revenue, driven by €477 million from Yorvipath and €206 million from Skytrofa. Q4 operating profit hit €10 million and cash flow reached €73 million, leaving €616 million in cash at year‑end. Management guided 2026 operating cash flow of roughly...
This Compound Enhances Long-Term Memory of Mice — but only in Females
Researchers injected acetate, a common metabolic by‑product, into mice and tested long‑term memory using spatial and object‑recognition tasks. Female mice that received acetate showed significantly better performance 24 hours later, while male mice displayed little to no improvement. The memory...
Amphastar Pharmaceuticals Inc (AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals reported full‑year 2025 net revenues of $719.9 million, a modest 2% decline, while its flagship product Baqsimi grew 12% to $185.4 million. The company secured FDA approval for ipratropium bromide HFA (AMP‑007), gaining 180‑day generic exclusivity, and announced a major...
Pacira Biosciences Inc (PCRX) Q4 2025 Earnings Call Transcript
Pacira BioSciences reported a record $726 million in total 2025 revenue and an all‑time high non‑GAAP gross margin of 80%, driven by growth in its flagship product EXPAREL. EXPAREL sales rose 7% year‑over‑year to $155.8 million, though the increase was partially offset...
Alpha Teknova Inc (TKNO) Q4 2025 Earnings Call Transcript
Alpha Teknova reported Q4 2025 revenue of $10.5 million, a 9% year‑over‑year increase and the fifth consecutive quarter of growth, driven primarily by its Lab Essentials catalog line. Lab Essentials revenue rose 16% to $8.3 million, while Clinical Solutions revenue slipped 13%...
Teleflex Inc (TFX) Q4 2025 Earnings Call Transcript
Teleflex reported 2025 adjusted EPS of $6.98, an 8.7% increase, while outlining a $2.03 billion divestiture plan that will net roughly $1.8 billion after tax. Management pledged to allocate $1 billion to share repurchases and use the remaining $800 million to reduce debt, bolstering...
Privia Health Group Inc (PRVA) Q4 2025 Earnings Call Transcript
Privia Health reported a robust 2025, with implemented providers rising 12.3% to 5,380 and attributed lives increasing 22.7% to 1.54 million. Practice collections grew 16.9% to $3.47 billion and adjusted EBITDA surged 38.8% to $125.5 million, delivering a 130% free‑cash‑flow conversion. The company...
OPKO Health Inc (OPK) Q4 2025 Earnings Call Transcript
OPKO Health reported a $369 million cash position for Q4 2025, driven by asset sales, BARDA funding and partnership payments. The company repurchased 34.6 million shares for $47 million and allocated $109 million to stock and convertible note buybacks. Diagnostics revenue dropped to $71.1 million, but...
Synaptic Correlates of Benzodiazepine Tolerance
Recent pre‑clinical work has mapped the synaptic changes that underlie benzodiazepine tolerance. Chronic exposure uncouples GABA(A) receptors from their benzodiazepine binding site, down‑regulates α1‑subunit mRNA, and reshapes receptor trafficking through auxiliary proteins such as Shisa7. These alterations weaken inhibitory signalling,...
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Transcript
Delcath Systems reported record 2025 revenue of $85.2 million, driven by over 40% volume growth and 28 REMS‑certified treatment centers. Gross margins held at 85% for Q4 and 86% for the full year, while adjusted EBITDA turned positive to $25.1 million and...
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics reported total revenue of $27.8 million for the quarter, a 6% year‑over‑year decline driven primarily by lower pricing in its OEM osteoarthritis pain‑management channel. Commercial channel revenue rose 22% to $12 million, powered by a 25% surge in...
Personalis Inc (PSNL) Q4 2025 Earnings Call Transcript
Personalis reported a record $18.2 million Q4 2019 revenue, a 38% year‑over‑year increase, and full‑year revenue of $65.2 million, up 73% from 2018. The VA Million Veteran Program (MVP) remained the core revenue driver, contributing $43.5 million for the year and $13.8 million in...
Biodesix Inc (BDSX) Q4 2025 Earnings Call Transcript
Biodesix reported fourth‑quarter 2021 revenue of $7.2 million and total 2021 revenue of $54.5 million, a 20% year‑over‑year increase driven by strong growth in its core lung‑diagnostic portfolio. Core lung‑test sales jumped 49% to $18.7 million, while COVID‑19 testing revenue collapsed, lifting the...
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Transcript
Organogenesis Holdings posted a record fourth‑quarter 2025, delivering $225.1 million in net product revenue, a 78% year‑over‑year increase driven largely by an 83% surge in advanced wound‑care sales. Gross profit rose to 78% of revenue and GAAP operating income jumped 519%...
Endometrium-Targeted mRNA-Lipid Nanoparticles for Treating Reproductive Conditions
Researchers have engineered ligand‑conjugated mRNA‑lipid nanoparticles that home specifically to the endometrium, delivering therapeutic mRNA directly to uterine tissue. In a murine model of endometrial injury, the targeted formulation restored embryo implantation rates to near‑normal levels. Safety profiling showed reduced...
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals reported a 37% year‑over‑year rise in Orladeyo revenue to $159.1 million in Q3 and lifted its 2025 sales guidance to $590‑$600 million. The company completed the divestiture of its European business, repaid a $200 million term loan and entered Q3 with...
Lantheus Holdings Inc (LNTH) Q4 2025 Earnings Call Transcript
Lantheus reported Q4 2025 revenue of $406.8 million and full‑year revenue of $1.54 billion, while announcing a strategic pivot to PET radiodiagnostics after completing the SPECT divestiture. The company highlighted acquisitions of Neuraceq and OCTEVY, positioning Neuraceq for triple‑digit growth and targeting...
Cytek Biosciences Inc (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences reported Q3 2025 revenue of $52.3 million, a modest 2% year‑over‑year increase driven by strong APAC growth and expanding recurring service and reagent streams. The company posted a net loss of $5.5 million and adjusted EBITDA of $2.5...
Relay Therapeutics Inc (RLAY) Q4 2025 Earnings Call Transcript
Heron Therapeutics reported full‑year 2025 net product sales of $155 million and adjusted EBITDA of $14.7 million, surpassing its guidance. Acute Care drove growth, with ZYNRELEF revenue up 48% YoY and the franchise expanding 57% overall, helped by the CrossLink IGNITE incentive program,...
Nautilus Biotechnology Inc (NAUT) Q4 2025 Earnings Call Transcript
Nautilus Biotechnology reported a 23% drop in operating expenses to $15.4 million for Q4 2025, driven by lower R&D and administrative costs, while ending the quarter with $156.1 million in cash and a reduced cash burn of $50.2 million. The...
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences reported $344.2 million revenue for 2025, beating its own guidance, and projected $340‑$350 million for 2026. Core test volumes surged, with TissueCypher reports up 86% to 39,014 and total reports reaching 105,053, while DecisionDx‑Melanoma grew modestly 9%. The company posted...
Vericel Corp (VCEL) Q4 2025 Earnings Call Transcript
Vericel Corp. reported record third‑quarter revenue of $67.5 million, driven by a 25% jump in MACI sales to $55.7 million and a 21% rise in burn‑care revenue. Margin expansion outpaced top‑line growth, with adjusted EBITDA climbing 70% to $17 million and gross profit...
Intellia Therapeutics Inc (NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics announced that the FDA has placed a clinical hold on its nex‑z MAGNITUDE and MAGNITUDE‑2 Phase III trials after a patient death and liver enzyme abnormalities. The company is implementing intensified safety monitoring and data reviews while awaiting regulatory...
Alta Equipment Group Inc (ALTG) Q4 2025 Earnings Call Transcript
Align Technology reported a record $1.05 billion Q4 2025 revenue, up 5.3% year‑over‑year, driven by strong clear‑aligner sales and expanding Systems & Services. Non‑GAAP operating margin improved to 26.1%, the highest since 2021, while cash balances rose to $1.09 billion. The company...
Prospective Study in High-Risk Individuals Supports Primary Prevention Trials in MS
A prospective analysis of 1,903 first‑degree relatives of multiple sclerosis (MS) patients found an incidence of 211 cases per 100,000 per year—about 100‑fold higher than the general population—and a median conversion time of two years, with diagnosis typically at age...
Trump’s Atypical Surgeon General Pick Faces Senate Scrutiny: Key Takeaways
President Trump nominated Casey Means, a 38‑year‑old Stanford‑trained physician‑influencer, as surgeon general, but she has not completed her residency and holds an inactive medical license. During her HELP Committee hearing, senators pressed her on vaccine positions, past social‑media statements, and...
Medical Device Maker UFP Technologies Warns of Data Stolen in Cyberattack
UFP Technologies, a $600 million medical‑device maker, disclosed a cyberattack detected on February 14 that compromised several IT systems. The company isolated the breach, removed the threat and engaged external advisors, but confirmed that data was stolen and some functions, such as...
EHR Strategy Becomes a Recruitment Lever for Health Systems
Chief medical information officers are reframing EHR and AI investments from pure operational upgrades to strategic tools for clinician recruitment, retention, and burnout mitigation. Leaders at Sentara Health report over 75% adoption of AI‑generated discharge summaries, citing significant time savings...
CMS Announces Actions Addressing Fraud
The Centers for Medicare & Medicaid Services (CMS) issued a Request for Information on a prospective rule called Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH), opening a 30‑day comment period after its Feb. 27 Federal Register publication. Simultaneously, CMS announced a...
14 Health Systems Extend EHR Contracts with Altera Digital Health
Fourteen health systems have signed multiyear extensions for Altera Digital Health’s Sunrise electronic health record, reinforcing the vendor’s foothold in the acute‑care market. The renewed contracts cover institutions such as Phoenix Children’s, St. Mary’s, Grand Lake Health System and Hospital for...
Radiopharmaceutical Targeted Toward Treatment-Resistant Cancer Put on FDA's Fast Track
Aktis Oncology announced that its investigational radiopharmaceutical AKY-1189 has earned FDA Fast Track designation. The drug targets Nectin‑4, present in 80‑90 % of urothelial cancers, and delivers the alpha‑emitter actinium‑225 directly to tumors. AKY-1189 is in a Phase 1b trial covering urothelial,...